Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.4
Journals
Medicina
Special Issues
Current Advances in Cardiovascular Disease Research
share announcement

Current Advances in Cardiovascular Disease Research

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 1994

Special Issue Editors

Prof. Dr. Ming-Jui Hung

E-Mail Website
Guest Editor
1. College of Medicine, Chang Gung University, Taoyuan, Taiwan
2. Department of Cardiology, Chang Gung Memorial Hospital, Keelung, Taiwan
Interests: vasospastic angina; echocardiography
Special Issues, Collections and Topics in MDPI journals
Dr. Tien-Hsing Chen

E-Mail Website
Guest Editor
Division of Cardiology, Keelung Chang Gung Memorial Hospital, Keelung 204, Taiwan
Interests: sudden cardiac death; cardiothoracic surgery; cardiology

Special Issue Information

Dear Colleagues,

Every country invests a lot of research funds into the field of cardiovascular diseases (CVDs); however, CVDs still remain an important clinical issue in the world despite significant progress in prevention and therapeutic management. Only through continuous efforts in basic research can we have the opportunity to apply research results in clinical practice. Subsequently, numerous research studies are being conducted to verify their effects clinically. This Special Issue will cover recent CVD research advances, including basic and clinical studies, with a particular emphasis on ischemic heart disease, peripheral vascular disease, and heart failure. Advancement in cardiac invasive and non-invasive image modalities are also welcomed. Recently, sodium glucose co-transporter 2 inhibitors have been shown to have benefits in CVD; therefore, articles relating to this topic are also welcomed as a part of this Special Issue.

We look forward to receiving your contributions, including review articles, systematic reviews/meta-analyses, and observational studies.

Prof. Dr. Ming-Jui Hung
Dr. Tien-Hsing Chen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • heart failure
  • ischemic heart disease
  • peripheral vascular disease
  • sodium glucose co-transporter 2 inhibitors

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 1750 KiB  
Article
PREVENT Equation: The Black Sheep among Cardiovascular Risk Scores? A Comparative Agreement Analysis of Nine Prediction Models in High-Risk Lithuanian Women
by Petras Navickas, Laura Lukavičiūtė, Sigita Glaveckaitė, Arvydas Baranauskas, Agnė Šatrauskienė, Jolita Badarienė and Aleksandras Laucevičius
Medicina 2024, 60(9), 1511; https://doi.org/10.3390/medicina60091511 - 16 Sep 2024
Cited by 1 | Viewed by 1476
Abstract
Background and Objectives: In the context of female cardiovascular risk categorization, we aimed to assess the inter-model agreement between nine risk prediction models (RPM): the novel Predicting Risk of cardiovascular disease EVENTs (PREVENT) equation, assessing cardiovascular risk using SIGN, the Australian CVD risk [...] Read more.
Background and Objectives: In the context of female cardiovascular risk categorization, we aimed to assess the inter-model agreement between nine risk prediction models (RPM): the novel Predicting Risk of cardiovascular disease EVENTs (PREVENT) equation, assessing cardiovascular risk using SIGN, the Australian CVD risk score, the Framingham Risk Score for Hard Coronary Heart Disease (FRS-hCHD), the Multi-Ethnic Study of Atherosclerosis risk score, the Pooled Cohort Equation (PCE), the QRISK3 cardiovascular risk calculator, the Reynolds Risk Score, and Systematic Coronary Risk Evaluation-2 (SCORE2). Materials and Methods: A cross-sectional study was conducted on 6527 40–65-year-old women with diagnosed metabolic syndrome from a single tertiary university hospital in Lithuania. Cardiovascular risk was calculated using the nine RPMs, and the results were categorized into high-, intermediate-, and low-risk groups. Inter-model agreement was quantified using Cohen’s Kappa coefficients. Results: The study uncovered a significant diversity in risk categorization, with agreement on risk category by all models in only 1.98% of cases. The SCORE2 model primarily classified subjects as high-risk (68.15%), whereas the FRS-hCHD designated the majority as low-risk (94.42%). The range of Cohen’s Kappa coefficients (−0.09–0.64) reflects the spectrum of agreement between models. Notably, the PREVENT model demonstrated significant agreement with QRISK3 (κ = 0.55) and PCE (κ = 0.52) but was completely at odds with the SCORE2 (κ = −0.09). Conclusions: Cardiovascular RPM selection plays a pivotal role in influencing clinical decisions and managing patient care. The PREVENT model revealed balanced results, steering clear of the extremes seen in both SCORE2 and FRS-hCHD. The highest concordance was observed between the PREVENT model and both PCE and QRISK3 RPMs. Conversely, the SCORE2 model demonstrated consistently low or negative agreement with other models, highlighting its unique approach to risk categorization. These findings accentuate the need for additional research to assess the predictive accuracy of these models specifically among the Lithuanian female population. Full article
(This article belongs to the Special Issue Current Advances in Cardiovascular Disease Research)
►▼ Show Figures

Figure 1

Review

Jump to: Research

23 pages, 1037 KiB  
Review
Galectin-1 in Cardiovascular Pathogenesis: Unraveling Dual Roles and Mechanistic Insights in Emerging Research
by Po-Yuan Chen, Chun-Yao Cheng, Chun-Chao Chen, Huan-Yuan Chen, Ju-Chi Liu, Wen-Rui Hao, Tzu-Hurng Cheng and Jin-Jer Chen
Medicina 2025, 61(6), 1020; https://doi.org/10.3390/medicina61061020 - 30 May 2025
Abstract
Galectin-1 (Gal-1), a β-galactoside-binding lectin, plays a complex role in cardiovascular diseases (CVDs), exerting both protective and pathological effects depending on the context. This review synthesizes findings from the past decade to explore Gal-1’s involvement in key aspects of CVD pathogenesis, including vascular [...] Read more.
Galectin-1 (Gal-1), a β-galactoside-binding lectin, plays a complex role in cardiovascular diseases (CVDs), exerting both protective and pathological effects depending on the context. This review synthesizes findings from the past decade to explore Gal-1’s involvement in key aspects of CVD pathogenesis, including vascular homeostasis, inflammation regulation, atherosclerosis progression, myocardial remodeling, and heart failure. While Gal-1 supports endothelial integrity and immune modulation, its dysregulation contributes to disease progression through pro-inflammatory signaling, fibrosis, and adverse cardiac remodeling. Emerging evidence suggests that Gal-1 holds potential as both a biomarker for risk assessment and a therapeutic target. However, critical knowledge gaps remain, particularly regarding its context-dependent effects, the limited scope of clinical trials, and unresolved mechanistic insights. Addressing these challenges will be essential to fully harness Gal-1’s therapeutic potential in cardiovascular medicine, guiding future research efforts toward precision interventions and clinical applications. Full article
(This article belongs to the Special Issue Current Advances in Cardiovascular Disease Research)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop